Eli Lilly (LLY) paid AlzeCure Pharma a $10 million upfront payment and completed the initial transaction under their collaboration and licensing agreement for the Alzheimer's disease project Alzstatin, AlzeCure said Tuesday.
The agreement gives Lilly global rights to Alzstatin, including drug candidate ACD680, and responsibility for its continued clinical development and commercialization.
The deal includes development and commercial milestones and mid-single-digit royalties, with total consideration potentially exceeding $1 billion, excluding royalties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments